CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 clinical trial evaluating the blood pressure lowering effects of CIN-107, […]